VivoSeq
Other

Stellate Ganglion Block

0

Pipeline Programs

7

Active Trials

0

Companies Involved

Stellate Ganglion Block is an early-stage landscape with 0 programs across 0 companies.

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

93/100

Attrition Rate

4/100

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

25

clinical trials

Completed14 · 56%
Not yet recruiting5 · 20%
Unknown status3 · 12%
Recruiting2 · 8%
Withdrawn1 · 4%

Trial Activity

25 trials

Stellate Ganglion Block
Recruiting·UUniversity of Minnesota·Phase 4·NCT06271707·48 enrolled
Stellate Ganglion Block in Longstanding Facial Nerve Palsy Patients
Not yet recruiting··N/A·NCT06742255·34 enrolled
Stellate Ganglion Block as Adjuvant Therapy to ca Channel Blocker
Completed··Phase 2·NCT04100824·40 enrolled
Ultrasound-Guided Stellate Ganglion Block With Botulinum
Completed··N/A·NCT05099835·60 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)